June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Clinical Outcomes of Eyes with Neovascular Lesions Composed of >50% Blood Treated with Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT)
Author Affiliations & Notes
  • Michael Altaweel
    Ophthalmology & Visual Science, Univ of Wisconsin-Madison, Madison, WI
  • Juan Grunwald
    Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Ebenezer Daniel
    Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Gui-Shuang Ying
    Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Jiayan Huang
    Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Glenn Jaffe
    Ophthalmology, Duke University, Durham, NC
  • Footnotes
    Commercial Relationships Michael Altaweel, None; Juan Grunwald, None; Ebenezer Daniel, None; Gui-Shuang Ying, None; Jiayan Huang, None; Glenn Jaffe, Heidelberg Engineering (C), Regeneron Pharmaceuticals (F), Neurotech USA (C), Abbott (C), Psivida (F), Pfizer (C), Bayer (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4162. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Altaweel, Juan Grunwald, Ebenezer Daniel, Gui-Shuang Ying, Jiayan Huang, Glenn Jaffe, ; Clinical Outcomes of Eyes with Neovascular Lesions Composed of >50% Blood Treated with Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2013;54(15):4162.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To compare baseline characteristics, treatment requirements, visual acuity (VA), and morphologic outcomes of eyes enrolled with > 50% of the total lesion composed of blood versus all other eyes enrolled in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

 
Methods
 

Cohort study within CATT. Participants were randomly assigned to treatment with ranibizumab or bevacizumab and to a dosing regimen of monthly injections for 2 years, PRN injections for 2 years, or monthly injections for 1 year and PRN injections the following year. Masked trained readers evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiograms (FA), and optical coherence tomography.

 
Results
 

84 of 1185 patients enrolled in CATT had lesions composed of >50% blood at baseline (B50 group). Baseline demographic characteristics were similar between the B50 group and the eyes with no or less blood (Other group) but lesion characteristics differed markedly. While CNV size was smaller in the B50 group (0.73 Disc Areas vs 1.83 DA; p <0.0001) the total lesion size was much larger (4.55 DA vs 2.31 DA; p <0.0001). Central retinal thickness was also greater in the B50 group (524 um vs 455 um). Mean baseline VA was worse in the B50 group (56 letters) than the Other group (60.9 letters). VA in the B50 group improved by a mean of 9.26 letters at 1 year and 9.44 letters at 2 years; similar to the improvement in the Other group (7.17 and 6.15, respectively). The percentage gaining 3 lines was similar for both groups (34.3% and 29.5% respectively). Eyes treated PRN required a similar number of injections in the two groups. Mean total lesion size in the B50 group decreased by a mean of 1.2 DA at 1 year and at 2 years while mean lesion size in the Other group increased by 0.33 DA at 1 year and 0.91 DA at 2 years (p<0.001). Mean retinal thickness also decreased more in the B50 group (-355 um vs -287um; p < 0.005). Lesion activity, as determined by leakage on FA, was similar between groups at both time intervals.

 
Conclusions
 

The B50 group had a visual prognosis similar to the Other group when treated according to the CATT protocol. Lesion size decreased markedly through 2 years. Eyes with neovascular AMD lesions composed of >50% blood can be managed clinically in a similar manner as those with less or no blood.

 
Keywords: 412 age-related macular degeneration • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 550 imaging/image analysis: clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×